The Lancet's 2026 GBD Study 2023 analysis, an observational systematic review aggregating data across 204 countries rather than an RCT, documents nearly 1.2 billion mental disorder cases with anxiety up 47% and depression 24% since 2019. Sample size is effectively global yet limited by uneven data quality in low-resource regions and reliance on modeled estimates. No conflicts of interest are declared by the Queensland Center authors. This epidemiological pivot exceeds pandemic effects alone, echoing patterns in a 2019 GBD precursor and WHO 2022 reports on social determinants where poverty and isolation amplify risk. Women and 15-19-year-olds bear disproportionate loads, tying into caregiving burdens and educational disruptions missed in surface coverage. Under-addressed ripple effects include projected workforce shrinkage and intergenerational transmission via adverse childhood experiences, demanding upstream policy over treatment expansion alone.